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Target audience: Researchers and clinicians interested in psychosis investigation, clinical staging, brain network analysis, connectomics. 
Purpose: Schizophrenia is a severe psychiatric disorder hypothesized to result from brain connectivity impairment1. Precocious brain alterations can already be 
highlighted in the early stages of the pathology2. According to the concept of clinical staging in psychotic disorders, brain connectivity might by more abnormal in more 
severe stages of the pathology, and altered connectivity measures might show progressive changes from prodromal to chronic phase3. In a recent diffusion-based 
analysis on 16 chronic schizophrenia patients and 15 healthy controls, we identified a spatially distributed set of brain regions, dubbed affected core or a-core, driving 
the loss of global brain network properties4. Investigating a cohort of 59 early psychosis patients, in the present study we question: (i) whether alterations of global brain 
network properties are already present in the early stage of the disease, and (ii) whether the a-core is precociously affected in the disease. We propose affected core 
network measures as possible markers of illness progression.  
Methods: 59 first episode psychosis patients having met the threshold for psychosis according to the CAARMS criteria5 (FEP, 42M/17F, 26+/-6yo), and 59 age and 
gender matched healthy controls (CTRL, 40M/19F, 26+/-6yo) underwent an MRI session composed by MPRAGE and diffusion spectrum imaging (DSI) sequences. 
Moreover, 16 chronic schizophrenia patients (SCHZ, 10M/6F, 26+/-6yo) and 15 age and gender matched healthy controls (CTRL, 8M/7F, 41+/-9yo) underwent the 
same MRI, as reported in4. For FEP patients, the number of hospitalizations before the MRI scan was recorded. Subject-wise structural connectivity matrices were 
generated combining MPRAGE segmentation into 82 cortical and subcortical regions, and DSI reconstruction and streamline tractography, according to6. Brain 
connectivity matrices were weighted by the relative streamline density as in4. Global and local integration and segregation network properties were quantified through 
classical graph measures, and particularly global efficiency, transitivity, nodal closeness centrality, and nodal local efficiency7. The affected core subnetwork was 
previously identified as driving the loss of global network properties in the cohort of 16 SCHZ patients and 15 CTRL, and includes 26 brain regions (figure (a))4. In the 
present study the a-core of CTRL, FEP and SCHZ subjects was characterized by the following measures: efficiency and transitivity computed within the a-core 
subnetwork; generalized fractional anisotropy (gFA) and inverse apparent diffusion coefficient (iADC) averaged over the a-core edges; a-core centrality within the 
overall brain network. As in4, the a-core centrality was characterized by comparing targeted attack toward the a-core itself with repeated random attacks, and computing 
the efficiency z-score (a-core centrality disruption) after targeted attack relative to its reference distribution4. Non-parametric Mann–Whitney U test (MWU, α=0.05) 
was used for group comparison. Multiple comparison correction was applied when necessary (FDR=0.05). A generalized linear model (GLM) was used to assess the 
relationship between a-core measures and illness stages, i.e. early psychosis patients to chronic schizophrenia stages, while controlling by age and gender. 
Results: Global network efficiency and transitivity, quantifying brain 
segregation and integration properties, were not affected in FEP patients 
compared to CTRL, as opposed to SCHZ patients4. None of the 82 brain 
regions' between-group comparison of nodal closeness centrality and local 
efficiency survived multiple comparison correction when comparing FEP and 
CTRL subjects. In order to assess affected core impairment in the early stage 
of psychosis, a-core measures were compared between FEP and CTRL 
subjects. Similarly to the SCHZ patients4, efficiency and transitivity computed 
within the a-core were reduced in FEP compared to CTRL (p<0.01, p<0.04). 
The efficiency z-score (a-core centrality) was tendentially diminished in FEP 
(p=0.07). GFA (p<0.003) and iADC (p<0.005) were decreased in FEP 
compared to CTRL when averaged over the a-core connecting tracts, 
indicating an early impairment of the a-core regions. GLMs including CTRL 
subjects, FEP, and SCHZ patients, and covariates age and gender, highlighted 
a statistically significant dependency between a-core measures (a-core 
efficiency, transitivity, gFA, iADC and efficiency z-score) and type 
1:CTRL/2:FEP/3:SCHZ (0.00004<p<0.05). Finally, FEP patients where 
subdivided into two sub-groups on the basis of the incidence of 
hospitalizations prior to the MRI scan: FEP subjects with 0 or 1 hospitalization (FEPa) and FEP with more than 1 hospitalization (FEPb). A-core efficiency and 
transitivity were significantly decreased in FEPb patients compared to CTRL (p<0.004, p<0.04), but between-group difference did not reach statistical significance 
when comparing FEPa patients and CTRL. A-core centrality, gFA and iADC were more consistently altered in FEPb than in FEPa compared to CTRL (lower p-values). 
Dispersion of efficiency z-score values for the four groups are reported in figure (b) (note that no statistical relationship between efficiency z-score and age and gender 
was found when considering the subject groups together or separately in a GLM). If we consider the hospitalizations incidence as possible indicator of  illness severity, 
this result support the a-core measures as possible biomarkers of psychosis progression. 
Discussion: Staging in psychotic disorders is clinically relevant for tailoring particular care to the severity of the disease. Importantly, neuroimaging techniques such as 
diffusion imaging, associated with advanced analysis tools such as graph theory, may help identifying biomarkers of illness progression, or characterizing specific 
stages of illness3. In this study we showed that global network properties, impaired in chronic schizophrenia, are not altered in the early stage of psychosis. Nonetheless, 
a distributed set of brain regions (a-core) extensively affected in chronic schizophrenia, is precociously impaired in the early stages of the disease. A GLM investigating 
a-core measures across the different psychosis stages suggests that a progressive impairment of the a-core brain subnetwork may worsen in time, eventually leading to a 
global brain efficiency loss not yet traceable in the earlier stages of the disease (b). Moreover the a-core subnetwork is more impaired in FEP patients presenting an 
higher number of hospitalizations before MRI.  
Conclusion: This study investigates psychosis progression with a neuroimaging and graph theory perspective. A distributed set of brain regions (a-core) affected in the 
chronic stage of the disease is precociously impaired in the early stages. We propose a-core network measures as possible markers of illness progression, while loss of 
global network efficiency and transitivity might characterize the advanced stages of the disease. 
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